Pralatrexate Clinical Trials
5 recruitingDrug
Phase 23Phase 12Phase 32
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin LymphomaRefractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07225985
Recruiting
Phase 3
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled34 locationsNCT06561048
Recruiting
Phase 2
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
PTCL
University of Virginia50 enrolled6 locationsNCT04747236
Recruiting
Phase 3
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Dizal Pharmaceuticals218 enrolled50 locationsNCT07234162
Recruiting
Phase 1Phase 2
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Lymphoma, T-Cell
University of Virginia148 enrolled1 locationNCT03161223